Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) Target Price at $11.13

Sutro Biopharma, Inc. (NASDAQ:STRO) has earned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $11.13.

A number of research analysts recently weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $11.00 price objective on shares of Sutro Biopharma in a report on Friday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Sutro Biopharma in a report on Monday, November 18th. JMP Securities reissued a “market outperform” rating and set a $17.00 price objective on shares of Sutro Biopharma in a report on Wednesday, December 11th. Wedbush restated an “outperform” rating and set a $8.00 target price on shares of Sutro Biopharma in a research report on Tuesday, December 10th. Finally, Wells Fargo & Company reduced their price target on shares of Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th.

Institutional Trading of Sutro Biopharma

Several institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC purchased a new stake in Sutro Biopharma in the 3rd quarter valued at approximately $77,000. Barclays PLC raised its holdings in shares of Sutro Biopharma by 385.3% in the third quarter. Barclays PLC now owns 273,019 shares of the company’s stock worth $944,000 after acquiring an additional 216,757 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Sutro Biopharma by 7.7% in the third quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company’s stock valued at $6,426,000 after acquiring an additional 132,015 shares in the last quarter. XTX Topco Ltd boosted its stake in shares of Sutro Biopharma by 222.0% during the third quarter. XTX Topco Ltd now owns 104,200 shares of the company’s stock valued at $361,000 after acquiring an additional 71,844 shares during the last quarter. Finally, Jane Street Group LLC increased its position in Sutro Biopharma by 30.7% during the 3rd quarter. Jane Street Group LLC now owns 108,192 shares of the company’s stock worth $374,000 after purchasing an additional 25,416 shares in the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Trading Down 4.1 %

Shares of STRO opened at $1.89 on Monday. The stock’s 50 day moving average is $2.91 and its two-hundred day moving average is $3.47. Sutro Biopharma has a twelve month low of $1.70 and a twelve month high of $6.13. The firm has a market capitalization of $155.85 million, a PE ratio of -1.17 and a beta of 1.09.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.